Trial Profile
A Study Evaluating Safety and Efficacy of Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Adenocarcinoma.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Bosutinib (Primary) ; Gemcitabine (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 03 Apr 2012 Actual patient number is 3 as reported by ClinicalTrials.gov.
- 03 Apr 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 19 May 2010 Actual initiation date (May 2010) added as reported by ClinicalTrials.gov.